Dow Jones closes well

0
1
Significantly passed the $ 1,900 mark


Despite the uncertain outcome of the US election, Wall Street presented itself with a clear profit on Wednesday.


TANNEN MAURY / AFP / Getty Images


© Provided by Finanz.net
TANNEN MAURY / AFP / Getty Images


The Dow Jones rose by a marginal 0.12 percent to 27,512.83 points at the opening and was able to gain significantly over the course of the year. He passed the round mark of 28,000 meters. At the close of trading, it was ultimately 1.34 percent higher at 27,847.93 points.

Despite the still completely unclear outcome of the US presidential election, the US stock markets continued their clear recovery course on Wednesday. In the run-up to this, stockbrokers had feared the scenario of a hanging game with a dragging election result and possible legal challenges. The list of winners was led by technology stocks and stocks from the healthcare sector.

Video: Dax rises – uncertainty after US election remains (Euronews)

Dax rises – uncertainty after US election remains

NEXT

NEXT

In the duel between Republican President Donald Trump and his Democratic challenger Joe Biden, no decision has yet been made. The fact that Trump declared himself the winner despite the ongoing vote count and threatened to go to the US Supreme Court to stop another vote count because of the delay in the election results also caused irritation.

The few company news in the shadow of the election crime caused significant price movements. So the shares jumped off Uber and Lyft at times double digitsafter the Californians had overturned a law in a referendum that the Uber– and Lift-Granted drivers the status of employees. The driving service brokers had announced that they would cease operations in the state, or at least limit them if it remained in force.

But the shares of Biogen from. Positive comments from the FDA on the effects of an Alzheimer’s drug, the shares catapulted over 40 percent to their highest level since the beginning of February. While two studies with the active ingredient aducanumab had produced contradicting results, FDA officials said on Wednesday that the effect in one study was “robust and extremely convincing”. This was taken as an indication that the authority could issue an approval for the agent.Redaktion finanzen.net / dpa-AFX

LEAVE A REPLY

Please enter your comment!
Please enter your name here